vTv Therapeutics Inc. EV/Sales

EV/Sales of VTVT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Sales growth rates and interactive chart. Compares the total enterprise value of a company to its sales. It is a more accurate measure of business value, as it takes into account cash and debt on the balance sheet. A company with large cash holdings and no debt will show a significantly lower EV/S than P/S ratio.

Highlights and Quick Summary

Current EV/Sales of vTv Therapeutics Inc. is 18.52 (as of December 30, 2019)
  • EV/Sales for the quarter ending September 29, 2020 was 2835.34 (a 6331.13% increase compared to previous quarter)
  • Year-over-year quarterly EV/Sales increased by 42180.67%
  • Annual EV/Sales for 2019 was 18.52 (a 511.88% increase from previous year)
  • Annual EV/Sales for 2018 was 3.03 (a -98.58% decrease from previous year)
  • Annual EV/Sales for 2017 was 213.52 (a 1688.45% increase from previous year)
Visit stockrow.com/VTVT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Sales of vTv Therapeutics Inc.

Most recent EV/Salesof VTVT including historical data for past 10 years.

Interactive Chart of EV/Sales of vTv Therapeutics Inc.

vTv Therapeutics Inc. EV/Sales for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 2835.34 44.09
2019 18.52 6.71 3.82 3.34 18.52
2018 3.03 1.77 5.05 19.05 3.03
2017 213.52 588.11 287.2 128.82 213.52
2016 11.94 30.81 -1.8 -25.05 11.94
2015 -48.03 -52.17 476.28 476.28 -48.03
2014 476.28 476.28 476.28
2013 476.28

Business Profile of vTv Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.